Physician profile
Devin Carey
NPI 1366822504
$12,835.32
in general payments reported to CMS, 2019-2025
54 companies · $2,602 in 2025
The $2,602 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $643 · 2021: $1,702 · 2022: $1,602 · 2023: $2,337 · 2024: $2,956 · 2025: $2,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,879 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,879.17 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,965.44 | 2021-2025 | Ubrelvy, Linzess, Qulipta |
| Novo Nordisk INC | $1,695.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,609.69 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,024.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $846.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $804.78 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $796.28 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Glaxosmithkline, LLC. | $673.28 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $355.14 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.63 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $283.80 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $243.39 | 2019-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $222.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $165.30 | 2019-2022 | |
| Esperion Therapeutics, INC. | $157.90 | 2021-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.